

Curriculum Vitae of Carmen Belli, MD, PhD

Current Position:

Oncology Consultant at European Institute of Oncology, Milan, Italy

Business Address:

Division of New Drug Development
European Institute of Oncology
Via Ripamonti 435
20141 Milan
Phone: +39 349 2820084
Email: carmen.belli@ieo.it ; cbelli77@gmail.com

Education:

2008: PhD in Medical and Surgical Oncology and Clinical Immunology, Seconda Università di Napoli, Naples, Italy
2005: Board-Certified in Oncology with honours (50/50 cum laude), Seconda Università di Napoli, Naples, Italy
2001: Medical Doctor with honours (110/110 cum laude), Seconda Università di Napoli, Naples, Italy

Brief Chronology of Activities:

2015-to date: General Medical Council full registration as medical practitioner with specialist registration (GMC reference number 7464846)
2013-to date: member of European Society of Medical Oncology (ESMO) and of Associazione Italiana Oncologia Medica (AIOM)
2012-to date: member of Associazione Italiana Studio Pancreas (AISP)
2009-2016: Oncology Consultant at San Raffaele Scientific Institute, Milan
2008-2010: Collaboration with Italian Mesothelioma Group (Gi.Me) for developing new drugs for the treatment of malignant mesothelioma
2008-2010: Advisor to Buzzi Foundation in drafting research projects and clinical trials on malignant mesothelioma
2007-2008: Training in Biological Mass Spectrometry at San Raffaele Scientific Institute, Milan
2005: Chairperson of the “Europa Donna Parlamento”
2001-2005: Fellowship in Medical Oncology at Seconda Università di Napoli, Naples
1998-2001: Training in Oncology at Oncology Department, Seconda Università di Napoli, Naples

Clinical Activity

March 2017: Clinical and Research activity at European Institute of Oncology Milan
2016-2017: Clinical activity at Oncology Department of Policlinico San Matteo - Pavia
2008-2016: Clinical activity at Oncology Department of San Raffaele Hospital. Main areas covered: mesothelioma, lung cancer, upper gastrointestinal cancer, pancreatic and biliary cancer, head and neck cancer
2001-2007: Clinical activity at Oncology Department of Seconda Università degli Studi di Napoli. Main areas covered: gastrointestinal and breast cancer
2004 -2005: Urgent care activity at Clinica Santa Rita - Atripalda (Avellino)
2004: Temporary replacement of general practitioner at ASL Napoli 1

Teaching

April 2015: Teaching at San Raffaele University. Subject of the lesson: head and neck cancer
May 2014: Teaching at San Raffaele University. Subject of the lesson: head and neck cancer
Dec 2018: Lesson for Master in Biotechnology

Research Activity

Dr. Belli has a wide range of clinical research experiences in mesothelioma, lung cancer, pancreatic cancer, upper gastrointestinal cancer, head and neck cancer, and breast cancer. She followed several clinical trials as co-investigator and wrote two clinical protocols and one biological research in pancreatic cancer.

She studied the role of diabetic condition and hyperinsulinism in the progression of pancreatic cancer and wrote a phase III clinical trial (PACT-17) evaluating the role of Metformin and polychemotherapy vs. polychemotherapy alone as first-line treatment of metastatic pancreatic cancer.

She also evaluated the role of Trabectedin as second-line therapy of metastatic pancreatic cancer in a phase II trial (PACT-18).

As for the biological research, she wrote a protocol aimed at evaluating the presence of cancer stem cell in patients affected by pancreatic cancer underwent to surgery or treated by neoadjuvant chemotherapy followed by surgery.

During her Ph.D., Dr. Belli analyzed serum proteomic profile of advanced lung cancer patients treated with EGFR Tyrosine Kinase Inhibitor (TKI). In a longitudinal study, she showed that serum proteomic profile can be used to classify likely responders to TKI therapy. This research laid the foundation of a randomized phase III trial (PROSE) assessing the predictive power of serum proteomic profile in non-small-cell lung cancer patients treated with erlotinib.

Clinical Trials “Co-Investigator”:

- 1) GIM 1: “A phase III randomised study of sequential EpiDoxorubicin plus Cyclophosphamide followed by Docetaxel (EC →D) versus the combination of 5-Fluorouracil, EpiDoxorubicin plus Cyclophosphamide (FEC) as adjuvant treatment of node-negative early breast cancer”
- 2) GIM 2: “A phase III randomized study of EC followed by Paclitaxel versus FEC followed by Paclitaxel, all given either every 3 weeks or 2 weeks supported by Pegfilgrastim, for node positive breast cancer patients”
- 3) GIM 4: “Letrozole Adjuvant therapy Duration (LEAD) study: standard versus long treatment. A phase III trial in postmenopausal women with early breast cancer”
- 4) GIM 5: “Letrozole adjuvant therapy after Tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients”
- 5) GIM 6 (Promise): “Prevention of chemotherapy-induced menopause by temporary ovarian suppression with Triptorelin versus control in young breast cancer patients. A randomized phase III multicenter study”
- 6) PROSE: “Randomized Proteomic Stratified Phase III Study of Second Line Erlotinib versus Chemotherapy in Patients with Inoperable Non Small Cell Lung Cancer”
- 7) PACT-12 “Phase II randomized trial of maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma”.
- 8) PACT-15 “Studio randomizzato di fase II-III di chemioterapia peri- o post-operatoria nel carcinoma del pancreas resecabile”
- 9) PACT-17 “Studio randomizzato di fase II di chemioterapia ± metformina nel carcinoma del pancreas metastatico”
- 10) PACT-18 “Salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma: A single-arm phase II trial
- 11) PACT-19 “Phase IB trial of *nab*-paclitaxel plus gemcitabine, capecitabine, and cisplatin in patients with stage III pancreatic adenocarcinoma”
- 12) MPACT “Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
- 13) APCAT: “A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant *nab*-paclitaxel (*nab*-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA)
- 14) MAESTRO “A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma”
- 15) CBGJ398X2204 “A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy
- 16) JANUS “A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas who have Failed or Are Intolerant to First-Line Chemotherapy”
- 17) D081FC00001: “A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has No Progressed on First Line Platinum Based Chemotherapy”

Publications:

Books

1) Book Author

- Problemi psicologici in Oncologia. Studio nelle pazienti con carcinoma mammario. Lega Tumori Avellino, 1995
- Aspetti clinici e psicologici del paziente neoplastico terminale. Cappuccio Editore, Avellino, 1997

2) Book Editor

- Malignant mesothelioma. Intech, May 2012

3) Book Chapter Author

- Mesotelioma pleurico. Medicina Interna Sistemica. Claudio Rugarli Sesta Edizione
- Tumori del polmone. Medicina Interna Sistemica. Claudio Rugarli Sesta Edizione

Peer Reviewed Journal Articles:

- 1) F. De Vita, F. Giuliani, G. Galizia, **C. Belli**, G. Aurilio, G. Santabarbara, F. Ciardiello, G. Catalano, M. Orditura. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. *Ann Oncol.* 2007;18 Suppl 6:vi 120-3
- 2) M. Giovannini, V. Gregorc, M.G. Viganò, E. Roca, C. Lazzari, A. Spreafico, **C. Belli**, G. Citterio, G. Rossoni, G. Donadoni, A. Corti, E. Villa, F. Caligaris-Cappio. Targeted delivery of TNF using NGR-TNF in combination with chemotherapy as an effective and tolerable strategy in a hepatocarcinoma patient. *Memo* 2008;1(1):43-6
- 3) F. Iovino, F. Ferraraccio, M. Orditura, G. Antonioli, F. Morgillo, T. Cascone, MR. Diadema, G. Aurilio, G. Santabarbara, R. Ruggiero, **C. Belli**, E. Irlandese, M. Fasano, F. Ciardiello, E. Procaccini, F. Lo Schiavo, G. Catalano, F. De Vita. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. *Cancer Invest* 2008;26(3):250-5
- 4) M. Giovannini, **C. Belli**, E. Villa, V. Gregorc. Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case? *J Thorac Oncol.* 2008;3(6):684-5
- 5) **Belli C.**, Fennell D., Giovannini M., Gaudino G., Mutti L. Malignant Pleural Mesothelioma: current treatments and emerging drugs. *Expert Opin Emerg Drugs.* 2009;14(3):423-37
- 6) Giovannini M., Gregorc V., **Belli C.**, Roca E., Lazzari C., Viganò MG., Serafico A., Villa E. Clinical significant of skin toxicity due to EGFR-targeted therapies. *J Oncol.* 2009; 2009: 849051. Epub 2009 Jun 22
- 7) **C. Belli**, S. Anand, G. Tassi, D. Fennell, L. Mutti. Translational therapies for malignant mesothelioma. *Expert Rev Respir Med.* 2010;4(2):249-60
- 8) A. Corti A, M. Giovannini M, **C. Belli**, E. Villa Immunomodulatory Agents with Antivascular Activity in the Treatment of Non Small Cell Lung Cancer: Focus on Tlr9 Agonists, Imids and Ngr-Tnf" *J Oncol.* 2010;2010:732680. Epub 2010 Jun 3
- 9) Giovannini M., Aldrighetti D., Zucchinelli P., **Belli C.**, Villa E. Antiangiogenic strategies in breast cancer management. *Crit Rev Oncol Hematol.* 2010;76(1):13-35
- 10) **C. Belli**, S. Anand, M. Panella, M. Giovannini, G. Tassi, D. Fennell, L. Mutti. Will antiangiogenic agents be the future for Mesothelioma Therapy? *Curr Med Chem.* 2010;17(27):3069-79
- 11) Cereda S., Reni M., Rognone A., Ghidini M., **Belli C.**, Longoni S., Fugazza C., Brioschi M., Nicoletti R., Balzano G., Passoni P., Villa E. XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. *Anticancer Res.* 2010;30(11):4785-90
- 12) Reni M., Cereda S., **Belli C.**, Villa E. Unity is strength: one, two, or more drugs against advanced pancreatic cancer? *Ann Oncol.* 2011;22(4):987
- 13) Reni M., Cereda S., Rognone A., **Belli C.**, Ghidini M., Longoni S., Fugazza C., Rezzonico S., Passoni P., Slim N., Balzano G., Nicoletti R., Cappio S., Doglioni C., Villa E. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). *Cancer Chemotherapy and Pharmacology* 2012;69(1):115-23
- 14) Cereda S., **Belli C.**, Reni M. Adjuvant treatment in biliary tract cancer: To treat or not to treat? *WJG* 2012;18(21):2591-6
- 15) **Belli C.**, Cereda S., Reni M. Role of taxanes in pancreatic cancer. *WJG* 2012;18(33):4457-65
- 16) **Belli C.**, Anand S., Cereda S., Reni M. Neoadjuvant therapy in resectable pancreatic cancer: A critical review. *Cancer Treatment Rev.* 2013;39(5):518-24
- 17) Cereda S, **Belli C**, Rognone A, Mazza E, Reni M. Second-line therapy in advanced biliary tract cancer: What should be the standard? *Crit Rev Oncol Hematol.* 2013;88(2):368-74
- 18) Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, **Belli C**, Danova M, Bergamo F, Franceschi E, Fugazza C, Ceraulo D, Villa E. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. *Eur J Cancer.* 2013; 49(17):3609-15
- 19) Mazza E, **Belli C**, Terreni M, Doglioni C, Losio C, Cantore M, Mambrini A, Reni M. Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature. *Crit Rev Oncol Hematol.* 2013;88(3):564-72
- 20) Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, **Belli C**, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. *Br J Cancer.* 2014;110(9):2165-9
- 21) Reni M, Dugnani E, Cereda S, **Belli C**, Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiore P, Sordi V, Lampasona V, Ceraulo D, Di Terlizzi G, Doglioni C, Falconi M, Piemonti L. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase 2 trial. *Clin Cancer Res.* 2016;22(5):1076-85
- 22) Leone F, Marino D, Cereda S, Filippi R, **Belli C**, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). *Cancer.* 2016;122(4):574-81.
- 23) Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, **Belli C**, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M. Capecitabine

with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. *Cancer Chemother Pharmacol.* 2016;77(1):109-14.

24) **Belli C**, Piemonti L, D'Incalci M, Zucchetti M, Porcu L, Cappio S, Doglioni C, Allavena P, Ceraulo D, Maggiora P, Dugnani E, Cangi MG, Garassini G, Reni M. Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. *Cancer Chemother Pharmacol.* 2016;77(3):477-84

25) **Belli C**, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, Curigliano G. Targeting the microenvironment in solid tumors. *Cancer Treat Rev.* 2018;65:22-32

26) Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, **Belli C**, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother.* 2018;19(3):299-305.

27) **Belli C**, Zuin M, Mazzarella L, Trapani D, D'Amico P, Guerini-Rocco E., Achutti Duso B, Curigliano G. Liver Toxicity in the Era of Immune Checkpoint Inhibitors: A practical Approach. *Crit Rev Oncol Hematol.* 2018

Conference Speaker:

- Francesco Sanfelice e la Teoria Blastomicetica del Cancro. Epidemie e Microbi nella Storia: Convegno della Società di Paleopatologia - Chieti, 16-17 Ottobre 1995
- I tumori iatrogeni. Nuovi Argomenti in Oncologia. La Corretta Pratica clinica nel Rapporto tra Operatori Sanitari, Istituzioni e Territorio. Lega Italiana per la Lotta contro i Tumori - Napoli 24 Maggio 2002
- Risposte Innovative nella Lotta al Tumore al Seno. Incontro con le Istituzioni. Aggiornamento medico-scientifico. Riunione di lavoro con le Associazioni. Lega Italiana per la Lotta contro i Tumori - Avellino, 15 Novembre 2007
- I^o Investigators' Meeting Studio HSRL-02-2007: "Randomized Phase III Study of Second Line Erlotinib versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer" - Milano, 18 Marzo 2008
- ToGet Erb 2010: "La nuova opzione terapeutica nel carcinoma mammario ErB2+" - Milano, 25 Novembre 2010
- I^o Investigators' Meeting Studio PACT-15: "Studio randomizzato di fase II-III di chemioterapia peri- o post-operatoria nel carcinoma del pancreas resecabile" - Milano, 7 Marzo 2011
- 35th National Congress of the Italian Association for the Study of the Pancreas (AISP). A 13-year single institution experience with 4-drug regimens in patients with advanced pancreatic adenocarcinoma - Peschiera del Garda (VE), 13-15th October 2011
- 36th National Congress of the Italian Association for the Study of the Pancreas (AISP). Clinical and translational results of a phase II randomized trial of maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma - Bologna 3-6th October 2012
- 36th National Congress of the Italian Association for the Study of the Pancreas (AISP). Metastatic site in pancreatic adenocarcinoma correlates with prognosis - Bologna, 3-6th October 2012
- La gestione umana, sociale e medica del paziente oncologico: dalla diagnosi alla fase terminale - Milano, 1 Dicembre 2012
- 38th National Congress of the Italian Association for the Study of the Pancreas (AISP). Enhanced Proteolytic Processing of CgA Predicts Overall Survival in Patients with Pancreatic Adenocarcinoma - Bologna 18-20th September 2014
- 38th National Congress of the Italian Association for the Study of the Pancreas (AISP). Phase IB trial of nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin in patients with stage III pancreatic adenocarcinoma - Bologna 18-20th September 2014
- 38th National Congress of the Italian Association for the Study of the Pancreas (AISP). Stage III Pancreatic Ductal Carcinoma (PDA): 10-year Experience with Combination Chemotherapy - Bologna 18-20th September 2014
- Tumore del Pancreas, Tra Prevenzione e Ricerca. Campagna "Pancrea" Creiamo Informazione. Milano, 25 Novembre 2014
- Combined Drug-Radiation Treatment. ESTRO School. Chengdu – China 13-16th June 2018
- 2nd Annual Paris Breast Cancer Conference. Paris – France 16-17 November 2018

Awards:

- 1999-2000: Top ranked student of Seconda Università di Napoli, Naples, Italy
- 2012: Best oral communication at 36th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Bologna, 4-6th October 2012
- 2014: Best oral communication at 38th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Bologna, 18-20th September 2014

Conferences:

- 1) Primo Congresso Epidemie e Microbi nella Storia - Chieti, 15-17 Ottobre 1995
- 2) Convegno Nazionale di Prevenzione Oncologia alle Soglie del Terzo Millennio - Napoli, 11-12 Giugno 1999
- 3) Corso teorico-pratico di Ecografia in Senologia - Frascati, 9-10 Novembre 2001
- 4) Corso teorico-pratico di Attualità in Senologia - Certosa di Padula, 17 Novembre 2001
- 5) Nuovi Argomenti in Oncologia. La corretta Pratica Clinica nel Rapporto tra Operatori Sanitari, Istituzioni e Territorio. Lega Italiana per la Lotta contro i Tumori - Napoli, 24 Maggio 2002

- 6) La malattia tromboembolica in oncologia e ginecologia: lo stato dell'arte - Napoli, 27 Giugno 2002
- 7) Linfoma di Hodgkin: quel 30% che non guarisce - Napoli, 16-17 Dicembre 2002
- 8) Corso teorico-pratico di ecografia senologica - Trani, 3-5 Aprile 2003
- 9) Corso teorico-pratico avanzato di Ecografia senologica - Padula 29-31 Maggio 2003
- 10) Corso di aggiornamento "Nuove frontiere tecnologiche per la chemioterapia in oncologia" - Napoli, 7 Maggio 2004
- 11) Investigators Meeting dello studio Promise - Genova 25 Maggio 2004
- 12) Corso di Informazione e Formazione per il Personale Esperto a Chemioterapici Antitumorali. 1^o Ciclo. Seconda Università degli Studi di Napoli - Napoli, 27 Ottobre, 11, 16 e 26 Novembre 2004
- 13) I trattamenti adiuvanti e neoadiuvanti in oncologia - Napoli, 11 Aprile 2005
- 14) 7th Milan Breast Cancer Conference - Milan, 15 - 17th June 2005
- 15) Trattamento sistemico del carcinoma mammario. Stato dell'arte e prospettive future - Roma, 21 Giugno 2005
- 16) Aggiornamento in senologia - Napoli, 4-5 Novembre 2005
- 17) Carcinoma della mammella dal "laboratorio alla clinica" - Napoli, 25 Novembre 2005
- 18) Gestione della paziente in postmenopausa con carcinoma della mammella in fase avanzata: dalla terapia alla comunicazione - Napoli, 27-28 Febbraio 2006
- 19) Up-Date sui Farmaci a Bersaglio Molecolare - Napoli, 10 Marzo 2006
- 20) La Terapia Ormonale Adiuvante del Carcinoma Mammario. Gli studi multicentrici italiani: GIM4 e GIM5 - Napoli, 16 Maggio 2006
- 21) Ductal Carcinoma in Situ of the Breast from Diagnosis to Treatment - Napoli, 31 Maggio 2006
- 22) 8^o Convegno Nazionale GOIM: "Dalle innovazioni biomolecolari e tecnologiche alla applicazione clinica" - Messina, 18-21 Giugno 2006
- 23) Terapia medica del carcinoma mammario: c'è veramente qualcosa di nuovo - Padula, 30 Giugno-1 Luglio 2006
- 24) 4^o Workshop Gruppo Italiano Mammella: "Trattamento adiuvante del carcinoma mammario. Stato dell'arte e prospettive future" - Roma, 16 Ottobre 2006
- 25) 2^o Corso Nazionale sui Problemi Metodologici e Statistici delle Sperimentazioni Cliniche in Oncologia - Napoli, 25-27 Ottobre 2006
- 26) Il dolore cronico dal sintomo alla malattia - Termoli, 10-11 Novembre 2006
- 27) "Second line Treatment of Advanced Non Small Cell Lung Cancer" - Napoli, 17 Aprile 2007
- 28) Highlights sul carcinoma dell'endometrio e nuovi orientamenti della ricerca clinica in oncologia ginecologica. Campobasso - 21 Maggio 2007
- 29) 9th Milan Breast Cancer Conference - Milan, 20-22th June 2007
- 30) Carcinoma mammario: ricerca clinica e traslazionale per la personalizzazione dei trattamenti - Roma, 25 Giugno 2007
- 31) Nuove prospettive terapeutiche nelle neoplasie mammarie Her2 positive - Napoli, 4 Luglio 2007
- 32) Tumori polmonari non microcitoma - Pavia, 26-27 Ottobre 2007
- 33) Mieloma multiplo: Strategie terapeutiche e supporti Educazionali per un impegno in oncoematologia - Milano, 23 Ottobre 2007
- 34) Screening for Lung Cancer and Management of Early Stage Disease - Rozzano, 25 Gennaio 2008
- 35) Nuovi farmaci in oncologia: dal laboratorio alla clinica - Bellinzona, 31 Gennaio-2 Febbraio 2008
- 36) hSR Scientific retreat (SR)² - Stresa, 17-19 Febbraio 2008
- 37) Corso di Perfezionamento in Pneumologia Oncologica - Torino, 25-29 Febbraio 2008
- 38) Terapie Mediche di Induzione e Complementari in Oncologia - Milano, 9 Maggio 2008
- 39) I Consensus Conference Italiana Mesotelioma Maligno della Pleura - Bologna, 20 Maggio 2008
- 40) STUDIO NEMESI "Studio osservazionale retrospettivo di modalità di trattamento adiuvante del carcinoma della mammella" - Roma, 30 Gennaio 2009
- 41) First International Workshop on Thoracic Oncology - Orbassano, 22-23th April 2009
- 42) XI Congresso Nazionale di Oncologia Medica - Milano, 10-13 Ottobre 2009
- 43) XXXIII Congresso Nazionale dell'Associazione Italiana Studio Pancreas - Rozzano, 15-17 Ottobre 2009
- 44) Dalla chemioterapia alla terapia anti-angiogenica: L'evoluzione del trattamento del carcinoma della mammella Her 2 negativo - Sorrento, 5-6 Marzo 2010
- 45) La metodologia della sperimentazione clinica - Milano, 7 Maggio 2010
- 46) Capecitabina: il suo ruolo nel carcinoma al seno - Milano, 28-29 Maggio 2010
- 47) 35th ESMO Congress - Milan, 8-12th October 2010
- 48) ToGet Erb 2010 - La nuova opzione terapeutica nel carcinoma mammario ErbB2+. Milano, 25 Novembre 2010
- 49) 35th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Peschiera del Garda, 13-15th October 2011
- 50) 48th ASCO Annual Meeting - Chicago, 1-5th June 2012
- 51) 36th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Bologna 3-6th October 2012
- 52) La gestione umana, sociale e medica del paziente oncologico: dalla diagnosi alla fase terminale - Milano, 1 Dicembre 2012
- 53) Hospital Program in HBV - Milano, 29 Gennaio 2013
- 54) Atlante SCCHN: decidere, sostenere, curare insieme. Assago (Milano), 9 Maggio 2013
- 55) 45th Annual Meeting of the European Pancreatic Club. Zurich, 26-28th June 2013
- 56) 38th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Bologna 18-20th September 2014
- 57) XVI Congresso Nazionale di Oncologia Medica - Roma, 24-26 Ottobre 2014
- 58) Janus 1 Investigators' Meeting. Lisbon 6-8th November 2014

- 59) 1st Annual Paris Breast Cancer Conference™. Paris 13-14th October 2017
 60) Grandangolo 2017. Un anno di Oncologia. XIX edizione. Genova, 14-15 Dicembre 2017
 61) 43rd ESMO Congress - Munich, 19-23rd October 2018

Abstracts:

- 1) Francesco Sanfelice e la teoria blastomimetica del cancro. I Congresso Società Italiana di Paleopatologia - Chieti, 16-17 Ottobre 1995
- 2) Dacarbazina (DTIC) + Interferone α -2 β (r-IFN) nel trattamento del melanoma maligno metastatico. Melanoma: Meeting Nazionale per Medici di Famiglia, Dermatologi e Chirurghi. Istituto Europeo di Oncologia - Milano, 26-27 Giugno 1997
- 3) Monochemioterapia con Gemcitabina nei pazienti "elderly" con NSCLC avanzato. Tumori in Età Geriatrica. II Congresso Nazionale - Roma, 7 Ottobre 1998
- 4) The use of transdermic fentanyl (TDF) in the treatment of chronic cancer pain. New Dimensions in Cancer Biology and Therapy - Naples, 24-25th September 1998
- 5) Stereotactic Needle Biopsy for Occult Breast Lesion: A Minimally Invasive Alternative. I Congresso Nazionale di Oncologia Medica - Roma, 24-28 Ottobre 1999
- 6) Paclitaxel (P) 3-Hours Infusion Plus Epirubicin (E) as First Line Therapy for Advanced Breast Cancer (ABC) Patients: A Preliminary analysis. I Congresso Nazionale di Oncologia Medica - Roma, 24-28 Ottobre 1999
- 7) Ruolo del Pamidronato disodico nel controllo del dolore da metastasi ossee e nel miglioramento della qualità di vita nelle neoplasie in fase avanzata. XXV Congresso Nazionale SIT. Società Italiana Tumori – Strategie Terapeutiche in Oncologia alle soglie del XXI Secolo - Sorrento 17-21 Novembre 1999
- 8) Vinorelbina + Gemcitabina nel trattamento del carcinoma polmonare non a piccole cellule (NSCLC) nei pazienti anziani. XXV Congresso Nazionale SIT. Società Italiana Tumori – Strategie Terapeutiche in Oncologia alle soglie del XXI Secolo - Sorrento 17-21 Novembre 1999
- 9) Subclinical lesion of the breast: our trial. 2nd Milan Breast Cancer Conference. Milan, June 14-16th, 2000
- 10) The role of core biopsy with 14 Gauge needles in the diagnosis of atypical ductal hyperplasia of the breast. 3rd Milan Breast Cancer Conference - Milan, 13-15th June 2001
- 11) The association chemo-radiotherapy in the treatment of locally advanced pancreatic cancer. Second International Cancer Congress - Rovigo, 5-7th December 2001
- 12) Trattamento integrato chemioradioterapico nei carcinomi avanzati del distretto cervico-cefalico. IV Congresso Interregionale AIOM - Firenze, 19-20 Aprile 2002
- 13) Treatment of multiple bone metastases with anastrozole plus radiotherapy in elderly patients with advanced breast cancer. 4th Milan Breast Cancer Conference - Milan, 5-7th June 2002
- 14) Associazione di Gemcitabina + Mitoxantrone nel trattamento del carcinoma mammario metastatico: nostra esperienza. Workshop: Marcatori Molecolari Emergenti in Oncologia: Terapia mirata, Indicatori di Risposta, Chemioprevenzione. International Cancer Center - Rovigo, 20 Settembre 2002
- 15) Hormonotherapy for metastatic breast cancer in patients with multiple bone metastases. XII Congresso Nazionale AIRO - Cagliari, 13-16 Ottobre 2002
- 16) Rituximab in the immunological treatment of severe post-fludarabine cytopenia: a case report. XXXIX Congress of the Italian Society of Hematology - Rome, 26-29th October 2003
- 17) Elevati livelli sierici perioperatori di VEGF in pazienti con carcinoma del colon. Giornate Scientifiche. Seconda Università degli Studi di Napoli - Napoli, 9-11 Giugno 2004
- 18) Studio di fase II di chemioterapia settimanale con Paclitaxel e Cisplatino associato alla radioterapia ed alla chirurgia come trattamento perioperatorio del cancro dell'esofago. Giornate Scientifiche. Seconda Università degli Studi di Napoli - Napoli, 9-11 Giugno 2004
- 19) Serum proteomic profile of non-small cell lung cancer (NSCLC) patients changes during therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-preliminary report. hSR Scientific Retreat (SR)² - Stresa, 17-19th February 2008
- 20) Serum proteomic profile is specific for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). hSR Scientific Retreat (SR)² - Stresa, 17-19th February 2008
- 21) Detection of serum proteomic profile predictive for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in 1st line chemotherapy. ASCO Annual Meeting - Chicago, 30th May-3rd June 2008
- 22) Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Preliminary study. ASCO Annual Meeting - Chicago, 30th May-3rd June 2008
- 23) The association between proteomic profile detected before 2nd/3rd line EGFR-TKIs and response to 1st line chemotherapy. ESMO Congress - Stockholm, 12-16th September 2008
- 24) Resistance to EGFR TKIs and serum proteomic profile in NSCLC patients. ESMO Congress - Stockholm, 12-16th September 2008
- 25) Impact of clinical parameters on outcome of patients treated with Gamma Knife Stereotactic radiosurgery for brain metastases from non small cell lung cancer. ESMO Congress - Stockholm, 12-16th September 2008
- 26) A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. ESMO Congress - Berlin, 20-24th September 2009
- 27) Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors ASCO Annual Meeting - Chicago, 4-8th June 2010

- 28) A 13-year single institution experience with 4-drug regimens in patients with advanced pancreatic adenocarcinoma (PA). 35th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Peschiera del Garda, 13-15th October 2011
- 29) An Observational Study of a Four-drug Combination in Patients with Advanced Pancreatic Adenocarcinoma. XIII Congresso Nazionale AIOM - Bologna, 5-7th November 2011
- 30) Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): Clinical and translational results of a phase II randomized trial. ASCO Annual Meeting - Chicago, 1-5th June 2012
- 31) Maintenance therapy with alpha-interferon (IFN- α) in locally advanced pancreatic cancer (LAPC): a pilot study. 44th European Pancreatic Club Meeting - Prague, 20-23rd June 2012
- 32) Metastatic site in pancreatic adenocarcinoma (PA) correlates with prognosis. 44th European Pancreatic Club Meeting - Prague, 20-23rd June 2012
- 33) Significant Association Between VEGF-A and ABCB1 Polymorphism and Survival in Metastatic Pancreatic Adenocarcinoma (MPA) Patients (PTS) Treated with Maintenance Sunitinib (MS). ESMO Congress - Vienna, 28th September-2nd October 2012
- 34) Clinical and Translational Results of a Phase II Randomized Trial of Maintenance Sunitinib or Observation in Metastatic Pancreatic Adenocarcinoma. 36th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Bologna, 4-6th October 2012
- 35) Metastatic Site in Pancreatic Adenocarcinoma Correlates with Prognosis. 36th National Congress of the Italian Association for the Study of the Pancreas (AISP) - Bologna, 4-6th October 2012
- 36) Clinical and translational results of a phase II randomized trial of Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA). XIV Congresso Nazionale AIOM - Bologna, 27-29th October 2012
- 37) A phase II trial of second line therapy with trabectedin in metastatic pancreatic adenocarcinoma (mPA). XIV Congresso Nazionale AIOM - Bologna, 27-29th October 2012
- 38) Metastatic site in pancreatic adenocarcinoma (PA) correlates with prognosis. XIV Congresso Nazionale AIOM -Bologna, 27-29th October 2012
- 39) Activity of *nab*-paclitaxel (*nab*-P) monotherapy in heavily pretreated pancreatic cancer (aPDAC) patients (pts): A multicenter retrospective analysis. C
- 40) K-ras status in biliary tract cancer (BTC): a single center experience. XV Congresso Nazionale AIOM – Milan, 11-13th October 2013
- 41) Phase Ib trial of *nab*-paclitaxel plus gemcitabine, capecitabine, and cisplatin in patients with stage III pancreatic adenocarcinoma. ESMO Congress - Madrid, 26-30th September 2014
- 42) Enhanced proteolytic processing of CgA predicts overall survival in patients with pancreatic adenocarcinoma. XVI Congresso Nazionale AIOM – Rome, 24-26th October 2014
- 43) Capecitabine (C) or capecitabine plus Mitomycin C (M): Results of a randomised phase II trial of second-line therapy in advanced biliary tract adenocarcinoma (BTA) XVI Congresso Nazionale AIOM – Rome, 24-26th October 2014
- 44) Phase Ib trial of *nab*-paclitaxel plus gemcitabine, capecitabine, and cisplatin in patients with stage III pancreatic adenocarcinoma. XVI Congresso Nazionale AIOM – Rome, 24-26th October 2014
- 45) Nab-Paclitaxel (Nab-P) is an active monotherapy in advanced pancreatic cancer (APDAC): Retrospective analysis of an Italian multiinstitutional experience in a heavily pretreated cohort of patients. XVI Congresso Nazionale AIOM – Rome, 24-26th October 2014
- 46) A Phase II, Open-label, Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Cancer. The Vecti-BIL Study. Gastrointestinal Cancers Symposium San Francisco 15-17th January 2015
- 47) Gemcitabine and Oxaliplatin (GEMOX) Chemotherapy with or without Panitumumab as First Line Treatment in Advanced Biliary Tract Cancer; updated survival results and subgroup analysis of the Vecti-BIL Study. 17th World Congress on Gastrointestinal Cancer. Barcelona, 1 – 4th July 2015
- 48) Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/-Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study. XVII Congresso Nazionale AIOM – Rome, 23-25th October 2015